Introduction. Epigenetics and cancer

Advances in Genetics

Volumn 70, Issue C, 2010, Pages 1-23

  Herceg, Zdenko ^a   Ushijima, Toshikazu ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BOOK; DNA METHYLATION; DNA REPAIR; ENVIRONMENT; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; GENOME IMPRINTING; HUMAN; NEOPLASM; NEOPLASMS;

ANIMALS; DNA METHYLATION; DNA REPAIR; ENVIRONMENT; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC IMPRINTING; HUMANS; NEOPLASMS;

EID: 77957346204     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-380866-0.60001-0     Document Type: Book

References (44)

1. Bartel D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
2. Belinsky S.A. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat. Rev. Cancer 2004, 4:707-717.
3. Brown R.C., Dwyer T., Kasten C., Krotoski D., Li Z., Linet M.S., Olsen J., Scheidt P., Winn D.M. Cohort profile: The International Childhood Cancer Cohort Consortium (I4C). Int. J. Epidemiol. 2007, 36:724-730.
4. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866.
5. Croce C.M., Calin G.A. miRNAs, cancer, and stem cell division. Cell 2005, 122:6-7.
6. Cubas P., Vincent C., Coen E. An epigenetic mutation responsible for natural variation in floral symmetry. Nature 1999, 401:157-161.
7. Egger G., Liang G., Aparicio A., Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463.
8. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8:286-298.
9. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer 2004, 4:143-153.
10. Feinberg A.P., Ohlsson R., Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7:21-33.
11. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., Iyer N.G., Perez-Rosado A., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
12. Gluckman P.D., Hanson M.A., Cooper C., Thornburg K.L. Effect of in utero and early-life conditions on adult health and disease. N. Engl. J. Med. 2008, 359:61-73.
13. Herceg Z. Epigenetics and cancer: Towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 2007, 22:91-103.
14. Hernandez-Vargas H., Lambert M.P., Le Calvez-Kelm F., Gouysse G., McKay-Chopin S., Tavtigian S.V., Scoazec J.Y., Herceg Z. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One 2010, 5:e9749.
15. Hitchins M.P., Ward R.L. Erasure of MLH1 methylation in spermatozoa-implications for epigenetic inheritance. Nat. Genet. 2007, 39:1289.
16. Hitchins M.P., Wong J.J., Suthers G., Suter C.M., Martin D.I., Hawkins N.J., Ward R.L. Inheritance of a cancer-associated MLH1 germ-line epimutation. N. Engl. J. Med. 2007, 356:697-705.
17. American Association for Cancer Research Human Epigenome Task Force; European Union, Network of Excellence, Scientific Advisory Board Moving AHEAD with an International Human Epigenome Project. Nature 2008, 454:711-715.
18. Jaenisch R., Bird A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat. Genet. 2003, 33(Suppl.):245-254.
19. Jiang Y.H., Bressler J., Beaudet A.L. Epigenetics and human disease. Annu. Rev. Genomics Hum. Genet. 2004, 5:479-510.
20. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
21. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
22. Jones P.A., Martienssen R. A blueprint for a Human Epigenome Project: The AACR Human Epigenome Workshop. Cancer Res. 2005, 65:11241-11246.
23. Laird P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 2003, 3:253-266.
24. Lister R., Pelizzola M., Dowen R.H., Hawkins R.D., Hon G., Tonti-Filippini J., Nery J.R., Lee L., Ye Z., Ngo Q.M., Edsall L., Antosiewicz-Bourget J., et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009, 462:315-322.
25. Lynch H.T. Hereditary nonpolyposis colorectal cancer (HNPCC). Cytogenet. Cell Genet. 1999, 86:130-135.
26. Maier S., Olek A. Diabetes: A candidate disease for efficient DNA methylation profiling. J. Nutr. 2002, 132:2440S-2443S.
27. Marquez V.E., Kelley J.A., Agbaria R., Ben-Kasus T., Cheng J.C., Yoo C.B., Jones P.A. Zebularine: A unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann. N. Y. Acad. Sci. 2005, 1058:246-254.
28. Martinez R., Martin-Subero J.I., Rohde V., Kirsch M., Alaminos M., Fernandez A.F., Ropero S., Schackert G., Esteller M. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 2009, 4:255-264.
29. McKinsey T.A., Olson E.N. Cardiac histone acetylation-therapeutic opportunities abound. Trends Genet. 2004, 20:206-213.
30. Mercer T.R., Dinger M.E., Mattick J.S. Long non-coding RNAs: Insights into functions. Nat. Rev. Genet. 2009, 10:155-159.
31. Molnar V., Tamasi V., Bakos B., Wiener Z., Falus A. Changes in miRNA expression in solid tumors: An miRNA profiling in melanomas. Semin. Cancer Biol. 2008, 18:111-122.
32. Murr R., Vaissiere T., Sawan C., Shukla V., Herceg Z. Orchestration of chromatin-based processes: Mind the TRRAP. Oncogene 2007, 26:5358-5372.
33. Nephew K.P., Huang T.H. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett. 2003, 190:125-133.
34. Rauch T.A., Zhong X., Wu X., Wang M., Kernstine K.H., Wang Z., Riggs A.D., Pfeifer G.P. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc. Natl. Acad. Sci. USA 2008, 105:252-257.
35. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007, 447:425-432.
36. Riboli E., Kaaks R. The EPIC Project: Rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int. J. Epidemiol. 1997, 26(Suppl. 1):S6-S14.
37. Sawan C., Vaissiere T., Murr R., Herceg Z. Epigenetic drivers and genetic passengers on the road to cancer. Mutat. Res. 2008, 642:1-13.
38. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
39. Shukla V., Vaissiere T., Herceg Z. Histone acetylation and chromatin signature in stem cell identity and cancer. Mutat. Res. 2008, 637:1-15.
40. Thomson J.P., Skene P.J., Selfridge J., Clouaire T., Guy J., Webb S., Kerr A.R., Deaton A., Andrews R., James K.D., Turner D.J., Illingworth R., et al. CpG islands influence chromatin structure via the CpG-binding protein Cfp1. Nature 2010, 464:1082-1086.
41. Urdinguio R.G., Sanchez-Mut J.V., Esteller M. Epigenetic mechanisms in neurological diseases: Genes, syndromes, and therapies. Lancet Neurol. 2009, 8:1056-1072.
42. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer 2005, 5:223-231.
43. Vaissiere T., Sawan C., Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat. Res. 2008, 659:40-48.
44. Waterland R.A., Jirtle R.L. Transposable elements: Targets for early nutritional effects on epigenetic gene regulation. Mol. Cell. Biol. 2003, 23:5293-5300.